Liothyronine sodium SR is under clinical development by Kashiv BioSciences and currently in Phase II for Hypothyroidism. According to GlobalData, Phase II drugs for Hypothyroidism have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Liothyronine sodium SR’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Liothyronine sodium SR overview
Liothyronine sodium (K-114) is under development for the treatment of hypothyroidism. It is a sustained-release formulation administered orally in the form of tablet. It targets Thyroid Hormone Receptor alpha and beta. The drug candidate is developed based on the GRANDE technology.
Kashiv BioSciences overview
Kashiv BioSciences (Kashiv) formerly known as Kashiv Pharma, is a pharmaceutical research company. It develops drug delivery platforms to create improved versions of medicines for patients and physicians. The company also develops innovative technologies, medicines, and life cycle management products. Kashiv provides services such as formulation development, analytical development and clinical supply manufacturing. It also offers contract research and development services to the pharmaceutical sector. Kashiv provides advanced deterrent technologies, formulation and controlled release technologies. The company works in partnership with pharmaceutical companies to commercialize its products. It operates a research and development facility in the US. Kashiv is headquartered in Bridgewater, New Jersey, the US.
For a complete picture of Liothyronine sodium SR’s drug-specific PTSR and LoA scores, buy the report here.